• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Despite Industry Buzz, Femtech Funding Still Lags

Share:

July 28, 2021

Femtech has been a hot topic in the digital health world for some time. Despite industry buzz about the tech, investment in the technology still lags behind other sectors.

According to Rock Health, femtech deals have only represented about 3% of digital health deals in the U.S. since 2011.

Reenita Das, partner and SVP for healthcare and life sciences at Frost and Sullivan, said recently femtech deals have actually declined.

“I actually don’t see this as an uptake at all. Digital health investment dollars in 2020 was $14.1 billion dollars. Femtech was only $254 million, so around 1.8% of total investment. 2018 was a banner year for femtech, as we got about 6% of the total digital health investment. Femtech investment has been going down despite popular belief.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Das, who will be speaking at HIMSS21 about the changing femtech industry, said that lack of funding is a leading challenge for the industry. She also noted men are disproportionately represented in software design, which can lead to men designing products used by women.

Women’s health needs to become more mainstream, said Das.

“We need mainstream global companies starting to invest and grow in this area. Currently, it is very much a female startup shop culture,” she said.

There is a lot of room for growth in the space. The global femtech market is expected to reach $1.15 billion by 2025, according to a Frost & Sullivan study.

That same study also described a recent shift in attention from primarily focusing on reproductive-age issues to untapped markets.

“Of the 4.2 billion women in 2030, 1.49 billion will be in the spring of life and almost the same number (over 1 billion) will be in the autumn stage. So I think the two biggies will be fertility and menopause.

“Today, fertility is the largest segment in terms of revenues of the femtech market- but menopause will see the greatest growth,” Das said. “By 2030, fertility femtech solutions will cross a billion dollars for sure. Menopause will have the fastest growth, close to 20 percent over the next several years.”

Other opportunity areas include mental health, autoimmune diseases, Alzheimer’s and dementia, women’s holistic products across different ages, and senior care centers for women, according to Das.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Who’s New Anti-Tobacco Program Pairs AI ‘virtual Health Worker’ with Nicotine Replacement TreatmentsWho’s New Anti-Tobacco Program Pairs AI ‘virtual Health Worker’ with Nicotine Replacement Treatments
  • Amring Pharmaceuticals Inc. Acquires LYSTEDA®Amring Pharmaceuticals Inc. Acquires LYSTEDA®
  • Bausch Health Confirms ‘Stalking Horse’ Agreement to Acquire Substantially All Assets of Synergy PharmaceuticalsBausch Health Confirms ‘Stalking Horse’ Agreement to Acquire Substantially All Assets of Synergy Pharmaceuticals
  • CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate DevelopmentsCEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
  • US Health Care Companies Begin Exploring Blockchain TechnologiesUS Health Care Companies Begin Exploring Blockchain Technologies
  • Cigna deal gets antitrust nod, positive sign for CVS/AetnaCigna deal gets antitrust nod, positive sign for CVS/Aetna
  • Novo follows Sanofi, Lilly with insulin price cut in USNovo follows Sanofi, Lilly with insulin price cut in US
  • Bright.md Raises $8M to Expand AI-Powered, Asynchronous Virtual CareBright.md Raises $8M to Expand AI-Powered, Asynchronous Virtual Care

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications